首页> 外文期刊>Journal of Endocrinological Investigation: Official Journal of the Italian Society of Endocrinology >Cardiovascular changes in patients with primary aldosteronism after surgical ormedical treatment
【24h】

Cardiovascular changes in patients with primary aldosteronism after surgical ormedical treatment

机译:外科药物治疗后原发性醛固酮增多症患者的心血管变化

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Data on the cardiovascular middle-term follow-up of patients with primary aldosteronism (PA) are scanty. Aim: To detect the cardiovascular effects of surgery in patients with aldosterone (ALD)-producing adenoma (APA) and of pharmacotherapy in those with bilateral adrenal hyperplasia (BAH), a prospective study involving 60 consecutive patients with PA was performed. Material/methods: Clinical, biochemical, and cardiovascular assessment was obtained before and after (31.5±4.4 months) surgery or proper medical treatment (32.1±5.0 months) in 19 and 41 patients, respectively. Results: As expected, plasma ALD normalized in all operated patients, while in the other group it did not change. Systolic and diastolic blood pressure decreased (p0.001) after both treatments. However, absolute and percentage reduction was significantly more pronounced (p0.01) in operated than in non-operated patients. Left ventricular (LV) mass showed significant reduction after surgery (LV mass g/m 2, p0.0007; LV mass g/m 2.7, p0.01), but no change after medical treatment, so that the differences between absolute and percentage values at follow-up were statistically significant (p0.01) between groups. Basal LV mass/m 2.7 was positively associated with age (p0.009), body mass index (p0.0008), drug number (p0.03), and ALD/plasma renin activity ratio (p0.01). Allocating the patients according to plasma ALD and cardiac parameters, patients who presented ALD reduction during the study also had a decrement in cardiac mass (p0.04). Conclusions: Our data indicate that in patients with PA the removal of ALD excess by surgery in APA is effective in reducing blood pressure and in improving cardiac parameters, while anti-hypertensive therapy in BAH shows less positive impact on cardiovascular system.
机译:背景:原发性醛固酮增多症(PA)患者的心血管中期随访数据很少。目的:为了检测产生醛固酮(ALD)的腺瘤(APA)患者的外科手术和患有双侧肾上腺增生(BAH)的药物治疗对心血管的影响,进行了一项涉及60名连续PA患者的前瞻性研究。材料/方法:分别在19例和41例患者的手术前后(31.5±4.4个月)或适当的药物治疗(32.1±5.0个月)进行了临床,生化和心血管评估。结果:正如预期的那样,所有手术患者的血浆ALD均恢复正常,而另一组则没有变化。两种治疗后收缩压和舒张压均降低(p <0.001)。但是,与未手术患者相比,手术患者的绝对值和百分比降低明显更为显着(p <0.01)。术后左心室质量明显降低(LV质量g / m 2,p <0.0007; LV质量g / m 2.7,p <0.01),但药物治疗后无变化,因此绝对值和百分比之间的差异两组之间的随访值具有统计学意义(p <0.01)。基础LV质量/ m 2.7与年龄(p <0.009),体重指数(p <0.0008),药物数量(p <0.03)和ALD /血浆肾素活性比(p <0.01)呈正相关。根据血浆ALD和心脏参数分配患者,研究期间出现ALD降低的患者心脏质量也有所减少(p <0.04)。结论:我们的数据表明,在PA患者中,通过APA手术清除过量的ALD可有效降低血压并改善心脏参数,而BAH的抗高血压治疗对心血管系统的积极影响较小。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号